apixaban

Overview

Apixaban is a small-molecule, direct oral anticoagulant (DOAC) that acts as a selective inhibitor of coagulation Factor Xa, a serine protease central to both the intrinsic and extrinsic pathways of the coagulation cascade. By blocking Factor Xa, apixaban prevents the conversion of prothrombin to thrombin, thereby inhibiting fibrin clot formation without requiring routine laboratory monitoring or dietary restrictions — features that distinguish it from vitamin K antagonists such as warfarin. It is administered orally, reaches peak plasma concentrations within approximately three to four hours, and is partially eliminated via renal excretion, a pharmacokinetic property that carries clinical significance in patients with chronic renal insufficiency or end-stage kidney disease.

Apixaban is approved for a range of thromboembolic indications, including stroke prevention in non-valvular atrial fibrillation (NVAF), treatment and secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and thromboprophylaxis following orthopedic surgery. Its favorable efficacy and safety profile relative to other anticoagulants — including warfarin, dabigatran, edoxaban, and rivaroxaban — has driven its widespread adoption in clinical practice and made it a central subject of comparative effectiveness and health economics research. Interest in apixaban expanded further during and after the COVID-19 pandemic, as the pandemic highlighted the clinical burden of thromboembolic complications across diverse patient populations.

Focus of Latest Publications

Recent publications on apixaban have focused on its use across several anticoagulation settings, with particular attention to postoperative venous thromboembolism prophylaxis, atrial fibrillation, and real-world dosing in patients with complex comorbidity. In bariatric surgery, two retrospective or comparative studies examined apixaban as an extended or post-discharge prophylactic option after sleeve gastrectomy or bariatric surgery more broadly, reflecting ongoing interest in oral alternatives to injectable regimens such as enoxaparin. These reports were framed around the need to clarify the safety and efficacy of apixaban in populations at elevated risk of postoperative venous thromboembolism.

In atrial fibrillation, apixaban was evaluated in both economic and clinical contexts. A Belgian payer-perspective analysis compared apixaban with warfarin, dabigatran, edoxaban, and rivaroxaban for non-valvular atrial fibrillation, assessing cost-effectiveness for stroke and systemic embolism prevention. Separately, a real-world registry study in patients with heart failure, non-valvular atrial fibrillation, and end-stage kidney disease examined off-label apixaban dosing, including underdosing and overdosing. Over long-term follow-up, the study reported no significant differences in systemic thromboembolic events, mortality, or bleeding between dosing groups, while CHA2DS2-VASc score remained an independent predictor of thromboembolic events.

Other recent work has explored apixaban in specific clinical and methodological settings. A pharmacokinetic monitoring study developed and validated an HPLC-tandem mass spectrometry method for measuring apixaban plasma concentrations in patients undergoing hip fracture surgery, reporting acceptable precision, low detection limits, and successful proof-of-concept application in three patient samples. In the ARTESiA program, apixaban was compared with aspirin in patients with subclinical atrial fibrillation detected by implanted cardiac devices, including a subgroup analysis in patients with pacemakers, implantable cardioverter-defibrillators, or implantable cardiac monitors. Another trial analysis compared bleeding outcomes on apixaban versus aspirin in ARCADIA, reflecting continued interest in the relative hemorrhagic risk of apixaban versus antiplatelet therapy.

Collectively, these publications highlight apixaban’s expanding evaluation beyond standard stroke prevention in atrial fibrillation to include postoperative prophylaxis, dose individualization in kidney disease, therapeutic drug monitoring, and comparative safety against aspirin. They also underscore ongoing efforts to define where apixaban fits among other oral anticoagulants, including rivaroxaban, and how it performs in higher-risk or less-studied patient groups.

Key Publications

Jun Safety of Apixaban for Postoperative Venous Thromboembolism Prophylaxis After Bariatric Surgery: A Single-Centre Retrospective Cohort Study. (Obesity surgery, 2026, PMID 42250128): "Direct oral anticoagulants such as apixaban offer practical advantages, but real-world safety data in bariatric populations are still evolving."
Jun Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in a Belgian healthcare setting. (Journal of medical economics, 2026, PMID 42223336): "This study assessed the cost-effectiveness of apixaban versus warfarin, dabigatran, edoxaban, and rivaroxaban for patients with NVAF from the Belgian payer perspective."
May Real-world off-label apixaban dosing and clinical outcomes in patients with heart failure and end-stage kidney disease. (Medicine, 2026, PMID 42216360): "Apixaban plays a crucial role in preventing cardioembolic events in patients with nonvalvular atrial fibrillation (NVAF)."
Jun An analytical method based on magnetic dispersive solid phase extraction combined with high performance liquid chromatography-tandem mass spectrometry for monitoring of apixaban plasma concentration in patients undergoing hip fracture surgery. (Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2026, PMID 41932170): "Nowadays, administration of apixaban as a new direct oral anticoagulant is highly increased to treat and prevent thromboembolic disorders in patients undergoing hip fracture surgery."
May Efficacy and safety of direct oral anticoagulants versus enoxaparin for extended thromboprophylaxis following sleeve gastrectomy. (Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 2026, PMID 41813545): "We evaluated the safety and efficacy of apixaban 2.5 mg twice daily relative to a weight-based dose of enoxaparin 40 mg or 60 mg twice daily for 30 days after discharge following sleeve gastrectomy."
Jun Apixaban Versus Aspirin and Risk of Hemorrhage in the ARCADIA Trial. (Annals of neurology, 2026, PMID 41741942): "We compared bleeding end points on apixaban versus aspirin in the ARCADIA trial."
Jun Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England. (British journal of clinical pharmacology, 2026, PMID 41406988): "Andexanet alfa was recommended by the National Institute for Health and Clinical Excellence (NICE) as an option in the management of life-threatening gastrointestinal bleeding in patients taking apixaban or rivaroxaban in May 2021."
Aug Apixaban for stroke prevention in subclinical atrial fibrillation detected by an implantable cardiac monitor: A subgroup analysis of ARTESiA. (Heart rhythm, 2025, PMID 40752875): "The ARTESiA trial randomized patients with a pacemaker (PM), implantable cardioverter-defibrillator (ICD), or implantable cardiac monitor (ICM) and with subclinical atrial fibrillation to either apixaban or aspirin."